Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Age is an independent predictor in pathological diagnosis of sarcoidosis: a retrospective analysis of diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration.
Kuwasaki E, Nagaoka T, Ihara H, Tsutsumi T, Nakamura A, Yoshikawa H, Yoshida T, Watanabe J, Ichikawa M, Koyama R, Shimada N, Takahashi K. Kuwasaki E, et al. Among authors: shimada n. J Thorac Dis. 2019 May;11(5):2175-2180. doi: 10.21037/jtd.2019.01.94. J Thorac Dis. 2019. PMID: 31285912 Free PMC article.
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K. Murakami A, et al. Among authors: shimada n. PLoS One. 2014 Jan 28;9(1):e86459. doi: 10.1371/journal.pone.0086459. eCollection 2014. PLoS One. 2014. PMID: 24489728 Free PMC article.
Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Nurwidya F, Takahashi F, Kobayashi I, Murakami A, Kato M, Minakata K, Nara T, Hashimoto M, Yagishita S, Baskoro H, Hidayat M, Shimada N, Takahashi K. Nurwidya F, et al. Among authors: shimada n. Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):332-8. doi: 10.1016/j.bbrc.2014.11.014. Epub 2014 Nov 15. Biochem Biophys Res Commun. 2014. PMID: 25446090
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T, Ko R, Mori K, Kato M, Yagishita S, Kanemaru R, Honma Y, Shibayama R, Koyama R, Shimada N, Takahashi K. Shukuya T, et al. Among authors: shimada n. Cancer Chemother Pharmacol. 2015 Oct;76(4):771-6. doi: 10.1007/s00280-015-2843-3. Epub 2015 Aug 11. Cancer Chemother Pharmacol. 2015. PMID: 26259641 Clinical Trial.
Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I, Takahashi F, Nurwidya F, Nara T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M, Shimada N, Suina K, Yoshioka Y, Sasaki S, Moriyama M, Moriyama H, Takahashi K. Kobayashi I, et al. Among authors: shimada n. Biochem Biophys Res Commun. 2016 Apr 22;473(1):125-132. doi: 10.1016/j.bbrc.2016.03.064. Epub 2016 Mar 17. Biochem Biophys Res Commun. 2016. PMID: 26996130
Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K, Kato M, Shukuya T, Mori K, Sekimoto Y, Ihara H, Kanemaru R, Ko R, Shibayama R, Tajima K, Koyama R, Shimada N, Nagashima O, Takahashi F, Sasaki S, Takahashi K. Nakamura K, et al. Among authors: shimada n. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6. BMC Cancer. 2017. PMID: 28464801 Free PMC article.
1,353 results